Growth analysis is the branch of fundamental analysis that asks how fast a company's business is expanding, how durable that expansion is, and — crucially — whether the growth is actually worth anything. It studies the top and bottom lines in motion: revenue, earnings, units, and customers over time, plus the underlying machinery that produces them (the size of the opportunity, the returns on reinvested capital, the adoption curve of the product, and whether growth is built or bought). The defining tension of the whole branch is that growth is the most seductive and the most misused concept in equity investing. A rising revenue line is exciting and easy to extrapolate, yet decades of evidence show that growth, by itself, is not a reliable source of stock returns — the price paid for it, and the quality behind it, usually matter more than the growth rate. Growth analysis exists to separate growth that compounds intrinsic value from growth that merely makes a company larger.

What this section covers

This section moves deliberately from opportunity to quality, because that is the order in which a growth thesis should be stress-tested. Each child node treats one layer in depth; this overview only maps them.

• Total Addressable Market (TAM) — the size of the prize and the runway behind a growth rate. The denominator question: a 40%-growing company is only durable if it has barely penetrated a large, expanding market. Also the most easily inflated number in the field (the "1% of a $100B market" fallacy). See the TAM node for top-down vs bottom-up sizing and the TAM→SAM→SOM funnel.

• Reinvestment & Compounding — the engine of value growth, not just size growth. Growth only creates value when capital is reinvested above the cost of capital (g ≈ Reinvestment Rate × Return on Capital; Higgins' g = Retention × ROE at the equity level). This is the node that distinguishes a great business from a merely large one. See it for ROIC/ROIIC, the runway-vs-quality trade-off, and the quality-factor evidence.

• S-Curves & Adoption — the shape of growth over time. New products diffuse along a logistic curve (Rogers' adopter categories, the Bass model, Moore's chasm); the same growth rate means opposite things pre-inflection versus near saturation. A diagnostic lens for "where on the curve is this company?" — not a precise forecaster.

• Organic vs Inorganic Growth — the source of growth. Did the company earn the revenue from its existing business or buy it through M&A? A 15% top line can be a thriving core or a roll-up illusion. The single highest-leverage decomposition in growth analysis. See it for the organic/FX/acquisition carve-out and the programmatic-acquirer nuance.

Together these answer four distinct questions about any growth story: how big can it get (TAM), is the growth worth anything (Reinvestment), where on the arc is it (S-Curves), and is the growth real or bought (Organic/Inorganic). Conventional growth-rate metrics (revenue CAGR, EPS growth, same-store sales) are the raw inputs these four lenses interpret.

The core tension: growth vs. the price of growth

The most important thing a growth analyst must internalize is that growth and stock returns are not the same thing. This is well documented:

• The value premium. Over the very long run (Fama–French US data back to 1926), the value research index has out-returned the growth index by roughly 2–3 percentage points annually — one practitioner summary (Alpha Architect) cites figures on the order of ~12–13% for value versus ~10% for growth, consistent with the well-documented positive HML (value-minus-growth) premium of roughly 3–5% per year in academic US data. The exact split varies by sample, methodology, and end date, but the direction is robust: the basket of cheap, slower-growing stocks beat the basket of expensive, faster-growing ones over the full history. Growth companies genuinely had higher ROE, ROA, and earnings growth; they still produced lower investor returns because of the price paid.

• Valuation reflects expected returns more than future growth. Research summarized by Alpha Architect and Knowledge@Wharton finds that the majority of the cross-sectional dispersion in valuation multiples maps to differences in future returns, not future earnings growth — one decomposition attributes roughly three-quarters to returns and one-quarter to growth. High multiples mostly signal low expected returns, not high coming growth.

• Naive extrapolation. A recurring finding (e.g., the "naive extrapolation"/rosy-forecast literature) is that the market and analysts over-extrapolate recent high growth, then are disappointed by mean reversion — the structural reason high-growth cohorts disappoint as investments.

The honest synthesis: fast growth is real and observable, but it is routinely over-priced, over-extrapolated, and mean-reverting. That is precisely why this branch emphasizes quality (reinvestment returns), durability (TAM runway, S-curve position), and authenticity (organic vs. bought) rather than the headline rate. Growth analysis done well is mostly the discipline of doubting a growth number.

When it matters — and when it doesn't

Growth analysis is most decisive for early-to-mid-life companies whose value is dominated by what they will become rather than what they earn today — software, consumer-platform, biotech, and any business priced at a high multiple. There, the entire thesis lives or dies on growth durability, so TAM credibility, reinvestment returns, and adoption stage do real work. It matters far less for mature, slow-growing, cash-return businesses (regulated utilities, mature staples), where margins, capital return, and valuation dominate.

Critically, this is a long-horizon, business-quality domain with no native short-term trading signal. None of the four child concepts is a chart pattern or a timing tool. They inform what a business is, not when a stock will move.

Strengths & limitations

The branch's strength is that it forces the right sequence of questions and refuses to take a revenue line at face value — every lens here exists to expose a different way a growth story can be hollow (no runway, low-return reinvestment, late-S decay, or bought-not-earned). Its limitation is that all four lenses lean on inputs that are unobservable or management-defined (the true ceiling of a TAM, future incremental returns, the adoption curve's parameters, the "organic" carve-out), so every output carries wide error bars. The single most common misuse across the entire branch is treating a high growth rate as self-evidently good — equating size growth with value creation, extrapolating a steep S-curve as inevitable, or reading a big TAM as attainable revenue. Growth analysis is the antidote to that instinct, not an excuse for it.

Sources

• Alpha Architect — Stock Valuations: Are They About Earnings or Expected Returns? (Fama–French value vs growth returns; returns vs growth decomposition): https://alphaarchitect.com/stock-valuations/
• Knowledge@Wharton — Why Stock Valuation Hinges More on Returns Than Future Earnings: https://knowledge.wharton.upenn.edu/article/why-stock-valuation-hinges-more-on-returns-than-future-earnings/
• The Naive Extrapolation Hypothesis and the Rosy-Gloomy Forecasts (over-extrapolation of growth): https://arxiv.org/pdf/1406.1733
• Investing.com Academy — How to Find Growth Stocks with Strong Fundamentals (practitioner growth-screen conventions, e.g. 15–20% growth thresholds): https://www.investing.com/academy/analysis/find-growth-stocks-strong-fundamentals/
• Morningstar — You Might Think Industry Growth Drives Stock Returns. Here's Why You'd Be Wrong: https://www.morningstar.com/stocks/you-might-think-industry-growth-drives-stock-returns-heres-why-youd-be-wrong
• Child nodes (this section): Total Addressable Market (TAM), Reinvestment & Compounding, S-Curves & Adoption, Organic vs Inorganic Growth — see each for primary sources (Higgins, Damodaran, Rogers, Bass, Moore, McKinsey).

Dispute flags: The value-premium / growth-underperformance evidence is robust over very long horizons but regime-dependent — growth strongly outperformed value over much of 2010–2021, so "value beats growth" is a long-run average, not a guarantee. Practitioner growth thresholds (15–20% revenue/EPS growth) are conventions, not laws. The return-vs-growth decomposition percentages are from specific studies and vary by sample.